CagriSema dual-chamber pen achieves near-universal ease of use and learning in adults with obesity or T2DM
Background
The global epidemics of obesity and type 2 diabetes necessitate effective and user-friendly treatment options. While fixed-dose combinations like CagriSema (cagrilintide and semaglutide) show significant efficacy in weight reduction and glycemic control, their real-world effectiveness hinges on patient adherence and proper administration. Complex or difficult-to-use injection devices can hinder compliance, leading to suboptimal outcomes despite potent pharmacology. This study addresses the critical need for an intuitive delivery system to maximize the therapeutic potential of this dual-agonist therapy.
Study Design
This usability study involved 150 adults (n = 85 with overweight/obesity, n = 65 with type 2 diabetes) who performed simulated once-weekly subcutaneous injections using the CagriSema dual-chamber pen. Participants received standardized training, after which their injection completeness and task durations were recorded. User feedback was collected via the Injection Device Experience and Acceptability-Ease of Use and Convenience Questionnaire (IDEA-ECQ), a validated instrument. The study assessed the device's ease of use, ease of learning, and overall convenience across diverse populations, irrespective of prior device experience.
Results
The CagriSema dual-chamber pen demonstrated high usability across all evaluated metrics. All but one participant (99.3%) successfully completed the simulated injection. Training for the device was remarkably efficient, with a median training time of just 3 minutes. The actual preparation and injection process was also rapid, taking a median of 15 seconds.
Participants overwhelmingly rated the device as easy/very easy to use (100%), easy/very easy to learn (98.7%), and convenient for injection (99.3%).
These positive results were consistent across both the overweight/obesity and type 2 diabetes populations and were not influenced by participants' prior experience with injection devices, indicating broad applicability.
Key Findings
- 99.3% of participants successfully completed the simulated injection.
- Median training time for the device was 3 minutes.
- Median time for preparation and injection was 15 seconds.
- 100% of participants rated the device easy/very easy to use.
- 99.3% found the injection with the pen convenient.
Why It Matters
High usability of the CagriSema dual-chamber pen is crucial for patient adherence and real-world treatment efficacy. For individuals managing obesity or type 2 diabetes, an intuitive and convenient injection device can significantly improve compliance with once-weekly subcutaneous administration, reducing the likelihood of missed doses or incorrect technique. This study suggests that the CagriSema pen design effectively minimizes barriers to self-injection, potentially translating to better clinical outcomes for users. The findings support the readiness of this delivery system for broad clinical adoption, ensuring that the therapeutic benefits of cagrilintide and semaglutide are accessible and consistently delivered.
cagrisema
cagrilintide
semaglutide
obesity
type 2 diabetes
usability